Market Place
Sourcing Support
Bristol Myers Presents Long-term EMERGENT Data in Schizophrenia
31 Oct 2024 //
BUSINESSWIRE
Zai Lab Reports Positive Data for KarXT in Schizophrenia
29 Oct 2024 //
BUSINESSWIRE
Bristol Myers Squibb to Present Data at Psych Congress 2024
28 Oct 2024 //
BUSINESSWIRE
BMS` schizophrenia gem Cobenfy was salvaged from the scrapheap
07 Oct 2024 //
FIERCE PHARMA
Segal Trials Key In FDA Approval Of Cobenfy For Schizophrenia
04 Oct 2024 //
BUSINESSWIRE
BMS taps Taye Diggs for schizophrenia educational campaign
22 May 2024 //
FIERCE PHARMA
Terran Develops TerXT Prodrug For Accelerated Schizophrenia Approval
20 May 2024 //
BUSINESSWIRE
Karuna’s schizophrenia drug succeeds in a second late-stage trial
21 Mar 2023 //
BIOPHARMADIVE
Segal Trials Participation in Study Shows Results From Phase 3 EMERGENT-2 KarXT
23 Aug 2022 //
BUSINESSWIRE
Karuna announces positive results from Phase III trial into schizophrenia
10 Aug 2022 //
PHARMA FILE
Zai Partner Karuna Announces Results from PIII EMERGENT-2 Trial of KarXT
08 Aug 2022 //
PRESS RELEASE
Karuna Therapeutics Reports Second Quarter 2022 Financial Results
08 Aug 2022 //
BUSINESS WIRE
Karuna Therapeutic IPO to Raise $89.2 Million for Neuropsychiatric Drug Devel...
28 Jun 2019 //
BIOSPACE
Karuna Therapeutic IPO to Raise $89.2 Million for Neuropsychiatric Drug
28 Jun 2019 //
BIOSPACE
Quest for safe muscarinic receptor agonists to tackle disaster prone CNS field
04 Jun 2019 //
ENDPTS
Karuna Pharms to Present Results of KarXT Phase 1 Study at ACNPP
11 Dec 2018 //
BUSINESSWIRE
Daily Brief: Karuna raises $42m for novel CNS approach
02 Aug 2018 //
PM LIVE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.